Improvements in distal lung function correlation with asthma symptoms after treatment with oral montelukast

Chest

Volumn 130, Issue 6, 2006, Pages 1726-1732

  Kraft, Monica ^a   Cairns, Charles B ^a   Ellison, Misoo C ^b   Pak, Juno ^b   Irvin, Charles ^c   Wenzel, Sally ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^c FLETCHER ALLEN HEALTH CARE   (United States)

Author keywords

Asthma; Distal lung; Montelukast; Pulmonary physiology; Residual volume

Indexed keywords

LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PLACEBO;

ADULT; AIRWAY CONDUCTANCE; ARTICLE; ASTHMA; CHEST TIGHTNESS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; EVALUATION; FEMALE; FORCED EXPIRATORY VOLUME; GENERAL CONDITION IMPROVEMENT; HUMAN; LUNG FUNCTION; LUNG MECHANICS; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESIDUAL VOLUME; SYMPTOM; TREATMENT DURATION; WHEEZING;

EID: 33749435086     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.130.6.1726     Document Type: Article

References (30)

1. Wenzel SE, Szefler SJ, Leung DY, et al. Bronchoscopic evaluation of severe asthma: persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med 1997; 156:737-743
2. Kraft M, Djukanovic R, Wilson S, et al. Alveolar tissue inflammation in asthma. Am J Respir Crit Care Med 1996; 154:1505-1510
3. Kraft M, Djukanovic R, Wilson S, et al. Lymphocyte and eosinophil influx into alveolar tissue in nocturnal asthma. Am J Respir Crit Care Med 1999; 159:228-234
4. Macklem PT, Mead J. The physiological basis of common pulmonary function tests. Arch Environ Health 1967; 14:5-9
5. Mauad T, Silva LF, Santos MA, et al. Abnormal alveolar attachments with decreased elastic fiber content in distal lung in fatal asthma. Am J Respir Crit Care Med 2004; 170:857-862
6. Leff JA, Busse WW, Pearlman D, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 1998; 339:147-152
7. Altman LC, Munk Z, Seltzer J, et al. A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist: Montelukast Asthma Study Group. J Allergy Clin Immunol 1998; 102:50-56
8. Laviolette M, Malmstrom K, Lu S, et al. Montelukast added to inhaled beclomethasone in treatment of asthma: Montelukast/Beclomethasone Additivity Group. Am J Respir Crit Care Med 1999; 160:1862-1868.
9. Biernacki WA, Kharitonov SA, Biernacka HM, et al. Effect of montelukast on exhaled leukotrienes and quality of life in asthmatic patients. Chest 2005; 128:1958-1963
10. Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: a randomized, controlled trial. Montelukast/ Beclomethasone Study Group. Ann Intern Med 1999; 130: 487-495
11. American Thoracic Society Board of Directors. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136:225-244
12. Kraft M, Pak J, Martin RJ, et al. Distal lung dysfunction at night in nocturnal asthma. Am J Respir Crit Care Med 2001; 163:1551-1556
13. Lemanske RF Jr, Sorkness CA, Mauger EA, et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA 2001; 285:2594-2603
14. Kaminsky DA, Wenzel SE, Carcano C, et al. Hyperpnea-induced changes in parenchymal lung mechanics in normal subjects and in asthmatics. Am J Respir Crit Care Med 1997; 155:1260-1266
15. Pichurko BM, Ingram RH Jr. Effects of airway tone and volume history on maximal expiratory flow in asthma. J Appl Physiol 1987; 62:1133-1140
16. Cherniack R. Pulmonary function testing. Philadelphia, PA: WB Saunders, 1977
17. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Res J 2005; 26:319-338
18. Littell RC, Milliken GA, Stroup WW, et al. SAS System for mixed models. Cary, NC: SAS Institute Inc, 1996
19. Evans JFD. Cloning and expression of leukotriene receptors. Clin Exp Allergy Rev 2001; 1:142-144
20. Hauber HP, Gotfried M, Newman K, et al. Effect of HFA-flunisolide on peripheral lung inflammation in asthma. J Allergy Clin Immunol 2003; 112:58-63
21. Mansell A, Dubrawsky C, Levison H, et al. Lung mechanics in antigen-induced asthma. J Appl Physiol 1974; 37:297-301
22. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108:184-190
23. Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18:254-261
24. Sutherland ER, Martin RJ, Bowler RP, et al. Physiologic correlates of distal lung inflammation in asthma. J Allergy Clin Immunol 2004; 113:1046-1050
25. Wagner EM, Bleecker ER, Perrnutt S, et al. Direct assessment of small airways reactivity in human subjects. Am J Respir Grit Care Med 1998; 157:447-452
26. Gelb AF, Zamel N. Unsuspected pseudophysiologic emphysema in chronic persistent asthma. Am J Respir Crit Care Med 2000; 162:1778-1782
27. Tammeling GJ, Sluiter HJ, Hilvering C, et al. Transpulmonary pressure at full inspiration and dynamics of the airways in patients with obstructive lung disease. Am Rev Respir Dis 1971; 103:38-48
28. Gelb AF, Schein A, Nussbaum E, et al. Risk factors for near-fatal asthma. Chest 2004; 126:1138-1146
29. Gold WM, Kaufman HS, Nadel JA. Elastic recoil of the lungs in chronic asthmatic patients before and after therapy. J Appl Physiol 1967; 23:433-438
30. McCarthy DS, Sigurdson M. Lung elastic recoil and reduced airflow in clinically stable asthma. Thorax 1980; 35:298-302